385 related articles for article (PubMed ID: 18814983)
21. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
Powles T; Murray I; Brock C; Oliver T; Avril N
Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
[TBL] [Abstract][Full Text] [Related]
22. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
[TBL] [Abstract][Full Text] [Related]
23. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
24. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
[TBL] [Abstract][Full Text] [Related]
25. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
Avril N; Adler LP
Radiol Clin North Am; 2007 Jul; 45(4):645-57, vi. PubMed ID: 17706529
[TBL] [Abstract][Full Text] [Related]
26. [Imaging of cancer activity and range of tumor involvement--applying to breast cancer].
Shibata K; Uno K; Wu J; Ko W
Rinsho Byori; 2007 Jul; 55(7):648-55. PubMed ID: 17718061
[TBL] [Abstract][Full Text] [Related]
27. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
28. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
29. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
Landheer ML; Steffens MG; Klinkenbijl JH; Westenberg AH; Oyen WJ
Br J Surg; 2005 Nov; 92(11):1363-7. PubMed ID: 16187254
[TBL] [Abstract][Full Text] [Related]
30. [Positron emission tomography in the management of cervix cancer patients].
Bonardel G; Chargari C; Gontier E; Bauduceau O; Soret M; Dechaud C; Fayolle M; Foehrenbach H
Cancer Radiother; 2009 Oct; 13(6-7):490-8. PubMed ID: 19699130
[TBL] [Abstract][Full Text] [Related]
31. Current Status of Hybrid PET/MRI in Oncologic Imaging.
Rosenkrantz AB; Friedman K; Chandarana H; Melsaether A; Moy L; Ding YS; Jhaveri K; Beltran L; Jain R
AJR Am J Roentgenol; 2016 Jan; 206(1):162-72. PubMed ID: 26491894
[TBL] [Abstract][Full Text] [Related]
32. [Molecular imaging with new PET tracers].
Beer AJ; Schwaiger M
Radiologe; 2007 Jan; 47(1):8-17. PubMed ID: 17136403
[TBL] [Abstract][Full Text] [Related]
33. Response to therapy in breast cancer.
Avril N; Sassen S; Roylance R
J Nucl Med; 2009 May; 50 Suppl 1():55S-63S. PubMed ID: 19380410
[TBL] [Abstract][Full Text] [Related]
34. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
35. Whole-body PET/CT-mammography for staging breast cancer: initial results.
Heusner TA; Freudenberg LS; Kuehl H; Hauth EA; Veit-Haibach P; Forsting M; Bockisch A; Antoch G
Br J Radiol; 2008 Sep; 81(969):743-8. PubMed ID: 18508873
[TBL] [Abstract][Full Text] [Related]
36. [Positron-emission tomography in urooncology].
Maurer T; Kübler H; Gschwend JE; Eiber M
Urologe A; 2015 Jul; 54(7):983-91. PubMed ID: 26109122
[TBL] [Abstract][Full Text] [Related]
37. Impact of the diagnostic methods on the therapeutic strategies.
Greco M; Agresti R; Giovanazzi R
Q J Nucl Med; 1998 Mar; 42(1):66-80. PubMed ID: 9646647
[TBL] [Abstract][Full Text] [Related]
38. Comparison of FDG-PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation.
Ford EC; Lavely WC; Frassica DA; Myers LT; Asrari F; Wahl RL; Zellars RC
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):595-602. PubMed ID: 18394814
[TBL] [Abstract][Full Text] [Related]
39. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
[TBL] [Abstract][Full Text] [Related]
40. Nuclear imaging in breast cancer.
Ferrara A
Radiol Technol; 2010; 81(3):233-46. PubMed ID: 20051596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
